Patient Toxicity Prediction: Identification Of Mucosal Injury Mediators Using Microarray Technology
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
There is no effective way to identify all patients that will develop toxic side-effects during the course of their cancer treatment. Current pharmacogenetic testing is too narrow. This project aims to examine whole-genome profiles of patient blood to determine if risk markers of toxicity can be identified prior to beginning treatment. I will do this by comparing oesophageal cancer patients who go on to develop severe toxicity with those who only get mild treatment side-effects.